Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Silymarin, derived from the milk thistle plant Silybum marianum, is widely used for self‐treatment of liver diseases, including hepatitis C virus (HCV), and its antiviral activity has been demonstrated in vitro and in HCV patients administered an intravenous formulation of the major silymarin flavonolignans, silybin A and silybin B. The safety and dose‐exposure relationships of higher than customary oral doses of silymarin and its acute effects on serum HCV RNA were evaluated in noncirrhotic HCV patients. Four cohorts of 8 patients with well‐compensated, chronic noncirrhotic HCV who failed interferon‐based therapy were randomized 3:1 to silymarin or placebo. Oral doses of 140, 280, 560, or 700 mg silymarin were administered every 8 hours for 7 days. Steady‐state exposures for silybin A and silybin B increased 11‐fold and 38‐fold, respectively, with a 5‐fold increase in dose, suggesting nonlinear pharmacokinetics. No drug‐related adverse events were reported, and no clinically meaningful reductions from baseline serum transaminases or HCV RNA titer were observed. Oral doses of silymarin up to 2.1 g per day were safe and well tolerated. The nonlinear pharmacokinetics of silybin A and silybin B suggests low bioavailability associated with customary doses of silymarin may be overcome with doses above 700 mg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Flaig, T. W., Gustafson, D. L., Su, L.-J., Zirrolli, J. A., Crighton, F., Harrison, G. S., Pierson, A. S., Agarwal, R., & Glodé, L. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-006-9019-2 · Cited by 315 · cited 1×
“A high-dose study using a phospholipid formulation of silybin A and B attained exposures 2 orders of magnitude greater than those achieved with customary doses.(27) However, grade 2/3 liver enzyme elevations with increased gastrointestinal complaints were reported.”
Result
Cited by
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
Federico, A., Dallio, M., & Loguercio, C. (2017) · Molecules · doi:10.3390/molecules22020191 · Cited by 492
Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review
Gillessen, A., & Schmidt, H. H.-J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01251-y · Cited by 490
Abenavoli, L., Izzo, A. A., Milić, N., Cicala, C., Santini, A., & Capasso, R. (2018) · Phytotherapy Research · doi:10.1002/ptr.6171 · Cited by 463
Hepatoprotective effect of silymarin
Vargas-Mendoza, N. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i3.144 · Cited by 447
Bijak, M. (2017) · Molecules · doi:10.3390/molecules22111942 · Cited by 414
Metadata
- Authors
- Hawke, R. L., Schrieber, S. J., Soule, T. A., Wen, Z., Smith, P. C., Reddy, K. R., Wahed, A. S., Belle, S. H., Afdhal, N. H., Navarro, V. J., Berman, J., Liu, Q., Doo, E., Fried, M. W., & The SyNCH Trial Group
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2010-04
- Volume
- 50
- Issue
- 4
- Pages
- 434-449
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2053309618
- Cited by
- 142
- References
- 1
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C. https://app.cochat.ai/papers/10.1177/0091270009347475
- The paper
- Hawke, R. L., Schrieber, S. J., Soule, T. A., Wen, Z., Smith, P. C., Reddy, K. R., Wahed, A. S., Belle, S. H., Afdhal, N. H., Navarro, V. J., Berman, J., Liu, Q., Doo, E., Fried, M. W., & The SyNCH Trial Group. (2010). Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270009347475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.